Stay updated on Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.

Latest updates to the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe page reflects a minor update to the platform/UI release revision, moving from “Revision: v3.5.2” to “Revision: v3.5.3.” This represents a technical/version change rather than a change to the displayed study information.SummaryDifference0.0%

- Check8 days agoChange DetectedRevision updated to v3.5.2 and the v3.5.0 revision was removed.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check37 days agoChange DetectedRevision: v3.5.0 added; Revision: v3.4.3 removed, indicating an update to the page’s revision history.SummaryDifference0.0%

- Check44 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. The new version is now displayed.SummaryDifference0.0%

- Check72 days agoChange DetectedAdded Revision: v3.4.2 and removed the funding-related notice (Revision: v3.4.1); these changes do not modify the study details, eligibility criteria, or outcomes presented on the page.SummaryDifference0.4%

- Check80 days agoChange DetectedAdded a government funding/operating status notice and updated the page revision tag from v3.4.0 to v3.4.1.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.